Q&As on Annual Reports

Questions and Answers on Listed Companies Annual Reports Singapore
Sort By: Company Name: Market:
Array
(
    [0] => WP_Post Object
        (
            [ID] => 9552
            [post_author] => 1
            [post_date] => 2021-10-01 11:30:09
            [post_date_gmt] => 2021-10-01 03:30:09
            [post_content] => 
            [post_title] => iX Biopharma Ltd
            [post_excerpt] => 
            [post_status] => publish
            [comment_status] => closed
            [ping_status] => closed
            [post_password] => 
            [post_name] => ix-biopharma-ltd-4
            [to_ping] => 
            [pinged] => 
            [post_modified] => 2021-10-06 17:26:54
            [post_modified_gmt] => 2021-10-06 09:26:54
            [post_content_filtered] => 
            [post_parent] => 0
            [guid] => https://sias.org.sg/?post_type=annual_reports&p=9552
            [menu_order] => 0
            [post_type] => annual_reports
            [post_mime_type] => 
            [comment_count] => 0
            [filter] => raw
        )

    [1] => WP_Post Object
        (
            [ID] => 5477
            [post_author] => 26
            [post_date] => 2018-10-03 17:09:56
            [post_date_gmt] => 2018-10-03 09:09:56
            [post_content] => 
            [post_title] => iX Biopharma Ltd
            [post_excerpt] => 
            [post_status] => publish
            [comment_status] => closed
            [ping_status] => closed
            [post_password] => 
            [post_name] => ix-biopharma-ltd-3
            [to_ping] => 
            [pinged] => 
            [post_modified] => 2019-05-28 12:32:12
            [post_modified_gmt] => 2019-05-28 04:32:12
            [post_content_filtered] => 
            [post_parent] => 0
            [guid] => https://sias.org.sg/?post_type=annual_reports&p=5477
            [menu_order] => 0
            [post_type] => annual_reports
            [post_mime_type] => 
            [comment_count] => 0
            [filter] => raw
        )

    [2] => WP_Post Object
        (
            [ID] => 4361
            [post_author] => 1
            [post_date] => 2018-07-26 19:42:19
            [post_date_gmt] => 2018-07-26 11:42:19
            [post_content] => 
            [post_title] => iX Biopharma Ltd
            [post_excerpt] => 
            [post_status] => publish
            [comment_status] => open
            [ping_status] => open
            [post_password] => 
            [post_name] => ix-biopharma-ltd-2
            [to_ping] => 
            [pinged] => 
            [post_modified] => 2018-08-14 16:22:19
            [post_modified_gmt] => 2018-08-14 08:22:19
            [post_content_filtered] => 
            [post_parent] => 0
            [guid] => http://sias2017.php-dp.com/annual_reports/ix-biopharma-ltd-2/
            [menu_order] => 0
            [post_type] => annual_reports
            [post_mime_type] => 
            [comment_count] => 0
            [filter] => raw
        )

    [3] => WP_Post Object
        (
            [ID] => 4129
            [post_author] => 1
            [post_date] => 2018-07-26 19:40:39
            [post_date_gmt] => 2018-07-26 11:40:39
            [post_content] => 
            [post_title] => iX Biopharma Ltd
            [post_excerpt] => 
            [post_status] => publish
            [comment_status] => open
            [ping_status] => open
            [post_password] => 
            [post_name] => ix-biopharma-ltd
            [to_ping] => 
            [pinged] => 
            [post_modified] => 2018-08-14 16:22:14
            [post_modified_gmt] => 2018-08-14 08:22:14
            [post_content_filtered] => 
            [post_parent] => 0
            [guid] => http://sias2017.php-dp.com/annual_reports/ix-biopharma-ltd/
            [menu_order] => 0
            [post_type] => annual_reports
            [post_mime_type] => 
            [comment_count] => 0
            [filter] => raw
        )

)
Array
(
    [company] => iX Biopharma Ltd
    [cid] => 5477,4361,4129
)
Array
(
    [post_type] => annual_reports
    [showposts] => -1
    [meta_key] => agm_date
    [orderby] => Array
        (
            [meta_value] => DESC
            [title] => ASC
        )

    [order] => DESC
    [paged] => 1
    [post_title_like] => iX Biopharma Ltd
    [meta_query] => Array
        (
            [key] => mark_as_upcoming_qa
            [value] => 
            [compare] => =
        )

)
Array
(
    [0] => WP_Post Object
        (
            [ID] => 9552
            [post_author] => 1
            [post_date] => 2021-10-01 11:30:09
            [post_date_gmt] => 2021-10-01 03:30:09
            [post_content] => 
            [post_title] => iX Biopharma Ltd
            [post_excerpt] => 
            [post_status] => publish
            [comment_status] => closed
            [ping_status] => closed
            [post_password] => 
            [post_name] => ix-biopharma-ltd-4
            [to_ping] => 
            [pinged] => 
            [post_modified] => 2021-10-06 17:26:54
            [post_modified_gmt] => 2021-10-06 09:26:54
            [post_content_filtered] => 
            [post_parent] => 0
            [guid] => https://sias.org.sg/?post_type=annual_reports&p=9552
            [menu_order] => 0
            [post_type] => annual_reports
            [post_mime_type] => 
            [comment_count] => 0
            [filter] => raw
        )

    [1] => WP_Post Object
        (
            [ID] => 5477
            [post_author] => 26
            [post_date] => 2018-10-03 17:09:56
            [post_date_gmt] => 2018-10-03 09:09:56
            [post_content] => 
            [post_title] => iX Biopharma Ltd
            [post_excerpt] => 
            [post_status] => publish
            [comment_status] => closed
            [ping_status] => closed
            [post_password] => 
            [post_name] => ix-biopharma-ltd-3
            [to_ping] => 
            [pinged] => 
            [post_modified] => 2019-05-28 12:32:12
            [post_modified_gmt] => 2019-05-28 04:32:12
            [post_content_filtered] => 
            [post_parent] => 0
            [guid] => https://sias.org.sg/?post_type=annual_reports&p=5477
            [menu_order] => 0
            [post_type] => annual_reports
            [post_mime_type] => 
            [comment_count] => 0
            [filter] => raw
        )

    [2] => WP_Post Object
        (
            [ID] => 4361
            [post_author] => 1
            [post_date] => 2018-07-26 19:42:19
            [post_date_gmt] => 2018-07-26 11:42:19
            [post_content] => 
            [post_title] => iX Biopharma Ltd
            [post_excerpt] => 
            [post_status] => publish
            [comment_status] => open
            [ping_status] => open
            [post_password] => 
            [post_name] => ix-biopharma-ltd-2
            [to_ping] => 
            [pinged] => 
            [post_modified] => 2018-08-14 16:22:19
            [post_modified_gmt] => 2018-08-14 08:22:19
            [post_content_filtered] => 
            [post_parent] => 0
            [guid] => http://sias2017.php-dp.com/annual_reports/ix-biopharma-ltd-2/
            [menu_order] => 0
            [post_type] => annual_reports
            [post_mime_type] => 
            [comment_count] => 0
            [filter] => raw
        )

    [3] => WP_Post Object
        (
            [ID] => 4129
            [post_author] => 1
            [post_date] => 2018-07-26 19:40:39
            [post_date_gmt] => 2018-07-26 11:40:39
            [post_content] => 
            [post_title] => iX Biopharma Ltd
            [post_excerpt] => 
            [post_status] => publish
            [comment_status] => open
            [ping_status] => open
            [post_password] => 
            [post_name] => ix-biopharma-ltd
            [to_ping] => 
            [pinged] => 
            [post_modified] => 2018-08-14 16:22:14
            [post_modified_gmt] => 2018-08-14 08:22:14
            [post_content_filtered] => 
            [post_parent] => 0
            [guid] => http://sias2017.php-dp.com/annual_reports/ix-biopharma-ltd/
            [menu_order] => 0
            [post_type] => annual_reports
            [post_mime_type] => 
            [comment_count] => 0
            [filter] => raw
        )

)
Array
(
    [company] => iX Biopharma Ltd
    [cid] => 5477,4361,4129
)
Array
(
    [post_type] => annual_reports
    [showposts] => 12
    [meta_key] => agm_date
    [orderby] => Array
        (
            [meta_value] => DESC
            [title] => ASC
        )

    [order] => DESC
    [paged] => 1
    [post_title_like] => iX Biopharma Ltd
    [meta_query] => Array
        (
            [key] => mark_as_upcoming_qa
            [value] => 
            [compare] => =
        )

)
AGM Date Company Market Annual Report SIAS Questions Company Response
AGM Date: 15/10/2021 15/10/2021 Company: iX Biopharma Ltd iX Biopharma Ltd Market: Catalist Catalist Annual Report: Download Download SIAS QuestionsWhat are the critical milestones to obtain the “marketing authorisation” for Wafesil... Read More
AGM Date: 19/10/2018 19/10/2018 Company: iX Biopharma Ltd iX Biopharma Ltd Market: Catalist Catalist Annual Report: Download Download SIAS Questions1. Can management help shareholders understand the R&D budget set aside... Read More
AGM Date: 24/10/2017 24/10/2017 Company: iX Biopharma Ltd iX Biopharma Ltd Market: Catalist Catalist Annual Report: Download Download SIAS Questions1. The group report a revenue increase of 10% to $6.4 million in 2017... 2. The group has developed a new pipeline of nutraceutical products and... 3. As disclosed in the Corporate Governance Report (page 29), a sum of $130,000... Read More Company Response1. Revenue of Chemical Analysis increased 7% in FY2017 over FY2016. There... 2. We have identified 5 major regions in which we are exploring launching... 3. During FY2017, Centrum Capital had been engaged to provide... Read More
AGM Date: 25/10/2016 25/10/2016 Company: iX Biopharma Ltd iX Biopharma Ltd Market: Catalist Catalist Annual Report: Download Download SIAS Questions1. New drug application is extremely costly and time consuming and shareholders may not be... 2. For the benefit of the current shareholders, the group must manage its expenses and cash... 3. In the Remuneration section in the Corporate Governance report (page 19), the... Read More Company Response1. Product: Wafermine™ Sublingual ketamine; PheoniX™ Sublingual... 2. Excluding share - based compensation, clinical t rials and... 3. RC commissioned Carrots Consulting to review the... Read More


Upcoming Q&A
Aedge Group Ltd Avi-Tech Electronics Ltd China Yuanbang Property Holdings Ltd
IPS Securex Holdings Ltd ISOTeam Ltd Karin Technology Holdings Ltd
SinoCloud Group Ltd TEHO International Inc Ltd Union Steel Holdings Ltd
Wing Tai Holdings Ltd